Research programme: immunocytokine anti-cancer therapeutics - ProvenanceAlternative Names: Anti-CSPG4-IL2; Anti-EpCAM-IL2
Latest Information Update: 05 May 2014
At a glance
- Originator Provenance Biopharmaceuticals
- Class Antibodies; Cytokines; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Malignant melanoma; Prostate cancer
Most Recent Events
- 05 May 2014 Preclinical trials in Prostate cancer in USA (Parenteral) prior to May 2014
- 05 May 2014 Preclinical trials in Malignant melanoma in USA (Parenteral) prior to May 2014